Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657671 | 0.73 | KMT2A (0.64) | MEN1KMT2ACYP1A2 | |
| SCHEMBL255964 | 0.73 | KMT2A (0.64) | MEN1KMT2ACYP1A2 | |
| SCHEMBL2875420 | 0.69 | CTSD (0.33) | MEN1KMT2ACYP1A2 | |
| SCHEMBL2874443 | 0.69 | HPGD (0.35) | MEN1KMT2A | |
| SCHEMBL632037 | 0.68 | MEN1 (0.37) | MEN1KMT2ACYP1A2 | |
| SCHEMBL6335483 | 0.65 | CTSD (0.37) | — | |
| SCHEMBL19194983 | 0.65 | PARP1 (0.36) | MEN1KMT2ACYP1A2 | |
| SCHEMBL255961 | 0.64 | MEN1 (0.46) | MEN1KMT2ACYP1A2 | |
| SCHEMBL8700 | 0.63 | — | — | |
| SCHEMBL31534672 | 0.61 | KMT2A (0.48) | MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | MEN1 306/4885KMT2A 3447/4885KDM4E 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.